ID   SW480/5FUR
AC   CVCL_AU16
DR   cancercelllines; CVCL_AU16
DR   Wikidata; Q54971156
WW   Provider; MD Anderson CCAC; -; https://www.mdanderson.org/content/dam/mdanderson/documents/core-facilities/Characterized%20Cell%20Line%20Core%20Facility/CCLC%20Cell%20Line%20List%20to%20Distribute.pdf
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_46345; 5-fluorouracil (5-FU).
CC   Sequence variation: Mutation; HGNC; HGNC:583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0546 ! SW480
SX   Male
AG   51Y
CA   Cancer cell line
DT   Created: 02-05-16; Last updated: 10-04-25; Version: 16
//